Top-News

ENTEST BIOMEDICAL News

Keine aktuellen Kursdaten verfügbar
WKN: A1JDGV
ISIN: US29383T1025
Typ: Aktie

ENTEST BIOMEDICAL News

29.09.17 - PR Newswire
Entest BioMedical Inc. Announces 3 Million Share Zander Therapeutics, Inc. Dividend to be Paid to Shareholders
Entest BioMedical Inc. Announces 3 Million Share Zander Therapeutics, Inc. Dividend to be Paid to Shareholders Dividend is Approximately 83% Payout of Zander's Issued and ...
13.09.17 - PR Newswire
Zander Therapeutics, Inc. Announces Appointment of Dr. Robin Beat Gasser to Scientific Advisory Board
Zander Therapeutics, Inc. Announces Appointment of Dr. Robin Beat Gasser to Scientific Advisory Board PR Newswire
26.07.17 - PR Newswire
Zander Therapeutics, Inc. Reports Research Demonstrating Ex-Vivo Immune Suppression of IL-17a and IL-2 in Dogs With Novel NR2F6 Activators
Zander Therapeutics, Inc. Reports Research Demonstrating Ex-Vivo Immune Suppression of IL-17a and IL-2 in Dogs With Novel NR2F6 Activators PR Newswire
27.06.17 - PR Newswire
Zander Therapeutics Inc. Announces Brian Devine, Former Chairman of PETCO, to Helm its Business Advisory Board
Zander Therapeutics Inc. Announces Brian Devine, Former Chairman of PETCO, to Helm its Business Advisory Board Zander is a subsidiary of Entest BioMedical Inc. and is ...
13.06.17 - PR Newswire
Entest BioMedical's Subsidiary Zander Therapeutics, Inc., Reports Its Series A Compounds Suppressed the Production of Multiple Cytokines Known to be Involved in Inflammation With No Toxicity In Canine
Entest BioMedical's Subsidiary Zander Therapeutics, Inc., Reports Its Series A Compounds Suppressed the Production of Multiple Cytokines Known to be Involved in Inflammation ...
07.06.17 - PR Newswire
Entest BioMedical's Subsidiary Zander Therapeutics, Inc. Reports on Preliminary Canine Experiments Testing New Anti-Inflammatory Drug Compounds
Entest BioMedical's Subsidiary Zander Therapeutics, Inc. Reports on Preliminary Canine Experiments Testing New Anti-​Inflammatory Drug Compounds PR Newswire
31.05.17 - PR Newswire
Entest BioMedical, Inc. Settles $841,531 of Principal Indebtedness Through the Issuance of Equity Securities
Entest BioMedical, Inc. Settles $841,531 of Principal Indebtedness Through the Issuance of Equity Securities Company views debt settlement as a positive step in cleaning up ...
23.05.17 - PR Newswire
Entest BioMedical Inc. Subsidiary Zander Therapeutics Discusses Developments in Medicinal Chemistry for Veterinary Applications of Cancer and Autoimmune Therapies Through Modulation of Checkpoint NR2F
Entest BioMedical Inc. Subsidiary Zander Therapeutics Discusses Developments in Medicinal Chemistry for Veterinary Applications of Cancer and Autoimmune Therapies Through ...
26.04.17 - PR Newswire
Entest BioMedical's Chairman Discusses its Subsidiary, Zander Therapeutics, Inc.'s Progress With Small Molecule Immunotherapies for Treating Cancer and Arthritis in Dogs
Entest BioMedical's Chairman Discusses its Subsidiary, Zander Therapeutics, Inc.'s Progress With Small Molecule Immunotherapies for Treating Cancer and Arthritis in Dogs ...
19.04.17 - PR Newswire
Entest BioMedical's Subsidiary, Zander Therapeutics, Inc., Initiates Ex Vivo Studies on Modulating NR2F6 in Canines
Entest BioMedical's Subsidiary, Zander Therapeutics, Inc., Initiates Ex Vivo Studies on Modulating NR2F6 in Canines PR Newswire
09.03.17 - PR Newswire
Entest BioMedical Inc.'s Subsidiary Zander Therapeutics Announces Appointment of Dr. Thomas Donnelly to Serve as Senior Veterinary Advisor
Entest BioMedical Inc.'s Subsidiary Zander Therapeutics Announces Appointment of Dr. Thomas Donnelly to Serve as Senior Veterinary Advisor PR Newswire
15.02.17 - PR Newswire
Entest BioMedical Inc.'s Zander Therapeutics Unit Announces Publication of Canine Cellular Immunotherapy Patent Application for Treating Cancer in Dogs
Entest BioMedical Inc.'s Zander Therapeutics Unit Announces Publication of Canine Cellular Immunotherapy Patent Application for Treating Cancer in Dogs PR Newswire
06.02.17 - PR Newswire
Entest BioMedical Inc.'s Subsidiary Zander Therapeutics Makes Key Additions to Management Team as the Company Prepares to Move Forward in the $63 Billion Veterinary / Pet Market Niche
Entest BioMedical Inc.'s Subsidiary Zander Therapeutics Makes Key Additions to Management Team as the Company Prepares to Move Forward in the $63 Billion Veterinary / Pet ...
06.02.17 - PR Newswire
Entest BioMedical Inc.'s Subsidiary Zander Therapeutics Makes Key Additions to Management Team as the Company Prepares to Move Forward in the $63 Billion Veterinary / Pet Market Niche
Entest BioMedical Inc.'s Subsidiary Zander Therapeutics Makes Key Additions to Management Team as the Company Prepares to Move Forward in the $63 Billion Veterinary / Pet ...
10.01.17 - PR Newswire
Entest BioMedical Inc.'s Subsidiary Zander Therapeutics Files Patent Application on its Proprietary NR2F6 Target for the Treatment of Exercise Induced Pulmonary Hypertension Frequently Found in Thorou
Entest BioMedical Inc.'s Subsidiary Zander Therapeutics Files Patent Application on its Proprietary NR2F6 Target for the Treatment of Exercise Induced Pulmonary Hypertension ...
21.12.16 - PR Newswire
Entest BioMedical, Inc. Chairman David Koos Discusses Zander Therapeutics Subsidiary and Future Plans for the Company Moving into 2017
Entest BioMedical, Inc. Chairman David Koos Discusses Zander Therapeutics Subsidiary and Future Plans for the Company Moving into 2017 PR Newswire
21.12.16 - PR Newswire
Entest BioMedical, Inc. Chairman David Koos Discusses Zander Therapeutics Subsidiary and Future Plans for the Company Moving into 2017
Entest BioMedical, Inc. Chairman David Koos Discusses Zander Therapeutics Subsidiary and Future Plans for the Company Moving into 2017 PR Newswire
19.10.16 - PR Newswire
Entest BioMedical's Zander Therapeutics Unit Files Composition of Matter Patent on NR2F6 Modulating Small Molecules in Canine and Feline Applications
Entest BioMedical's Zander Therapeutics Unit Files Composition of Matter Patent on NR2F6 Modulating Small Molecules in Canine and Feline Applications PR Newswire
24.09.15 - PR Newswire
Entest BioMedical Updates Company Status and Future Plans
Entest BioMedical Updates Company Status and Future Plans PR Newswire

Newssuche

Videos

newspaper
24.04.24
Technical Trading: AUD/USD mit Mega Chance
AUD/USD Long Typ: Turbo Open End WKN: UM0EHU Hebel: 6,42 Laufzeit: OpenEnd Einstieg: Market ... Mehr »